Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice

International Journal of Cancer

Volumn 116, Issue 6, 2005, Pages 870-875

  Hu, Ying ^a   Le Leu, Richard K ^a   Young, Graeme P ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Apoptosis; Carcinogen; Colorectal cancer; Intestinal epithelia; p53; Sulindac

Indexed keywords

AZOXYMETHANE; CARCINOGEN; PROTEIN P53; SULINDAC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; COLON CANCER; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; GENE DOSAGE; GENE MUTATION; GENOTOXICITY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZOXYMETHANE; COLONIC NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SULINDAC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23944475543     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21107     Document Type: Article

References (60)

1. Gupta RA, DuBois RN. Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology 1998;114:1095-8.
2. Newmark HL, Bertagnolli MM. Aspirin and colon cancer prevention. Gastroenterology 1998;115:1036.
3. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8.
4. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
5. Niitsu Y, Takayama T, Miyanishi K, Nobuoka A, Hayashi T, Kukitsu T, Takanashi K, Ishiwatari H, Abe T, Kogawa T, Takahashi M, Matsunaga T, et al. Chemoprevention of colorectal cancer. Cancer Chemother Pharmacol 2004;54:S40-3.
6. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004;31:12-21.
7. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293-7.
8. Din FV, Dunlop MG, Stark LA. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 2004;91:381-8.
9. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ. Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2003;2:885-92.
10. Babbar N, Ignatenko NA, Casero RA Jr, Gerner EW. Cyclooxygenase- independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem 2003;278: 47762-75.
11. Pasricha PJ, Bedi A, O'Connor K, Rashid A, Akhtar AJ, Zahurak ML, Piantadosi S, Hamilton SR, Giardiello FM. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995;109:994-8.
12. Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996;222:179-88.
13. Zhang T, Fields JZ, Ehrlich SM, Boman BM. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 2004;308: 434-7.
14. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 1995;83:493-501.
15. Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R, Ahnen DJ. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110-6.
16. Augenlicht LH, Heerdt BG, Mariadason JM, Yang W, Wilson AJ, Fragale A, Velcich A. Environment-gene interactions in intestinal cancer. Eur J Cancer Prev 2002;11(Suppl):S12-7.
17. Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer Chemoprevention and promotion. Cancer Res 1997; 57:1301-5.
18. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
19. Jacoby RF, Llor X, Teng BB, Davidson NO, Brasitus TA. Mutations in the K-ras oncogene induced by 1, 2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa. J Clin Invest 1991;87:624-30.
20. Vivona AA, Shpitz B, Medline A, Bruce WR, Hay K, Ward MA, Stem HS, Gallinger S. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 1993;14:1777-81.
21. Takahashi M, Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents 2004;95:475-80.
22. Shivapurkar N, Belinsky SA, Wolf DC, Tang Z, Alabaster O. Absence of p53 gene mutations in rat colon carcinomas induced by azoxymethane. Cancer Lett 1995;96:63-70.
23. De Filippo C, Caderni G, Bazzicalupo M, Briani C, Giannini A, Fazi M, Dolara P. Mutations of the Ape gene in experimental colorectal carcinogenesis induced by azoxymethane in F344 rats. Br J Cancer 1998;77:2148-51.
24. Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, Newmark HL, Chadburn A, Bertagnolli MM. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998;19:87-91.
25. Nugent KP, Spigelman AD, Phillips RK. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis Colon Rectum 1996;39:659-62.
26. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-9.
27. Barnes CJ, Cameron IL, Hardman WE, Lee M. Non-steroidal antiinflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer 1998;77: 573-80.
28. Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ, Rao CV. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 1999;59:3387-91.
29. Kuno T, Yamada Y, Hirose Y, Katayama M, Sakata K, Hara A, Saji S, Mori H. Induction of apoptosis by sulindac in azoxymethane-induced possible colonic premalignant lesions in rats. Jpn J Cancer Res 2002;93:242-6.
30. Hu Y, Le Leu R, Young GP. Absence of acute apoptotic response to genotoxic carcinogens ("AARGC") in p53 deficient mice is associated with increased susceptibility to azoxymethane-induced colon tumours. Int J Cancer (in press).
31. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995;55:1464-72.
32. Hu Y, Martin J, Le Leu R, Young GP. The colonic response to genotoxic carcinogens in the rat: regulation by dietary fibre. Carcinogenesis 2002;23:1131-7.
33. Ward JM. Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats. Lab Invest 1974;30:505-13.
34. Le Leu RK, Hu Y, Young GP. Effects of resistant starch and nonstarch polysaccharides on colonic luminal environment and genotoxin-induced apoptosis in the rat. Carcinogenesis 2002;23: 713-9.
35. Le Leu RK, Brown IL, Hu Y, Young GP. Effect of resistant starch on genotoxin-induced apoptosis, colonic epithelium, and lumenal contents in rats. Carcinogenesis 2003;24:1347-52.
36. Hong MY, Lupton JR, Morris JS, Wang N, Carroll RJ, Davidson LA, Elder RH, Chapkin RS. Dietary fish oil reduces O6-methylguanine DNA adduct levels in rat colon in part by increasing apoptosis during tumor initiation. Cancer Epidemiol Biomarkers Prev 2000;9:819-26.
37. Afford S, Randhawa S. Apoptosis. Mol Pathol 2000;53:55-63.
38. Renehan AG, Bach SP, Potten CS. The relevance of apoptosis for cellular homeostasis and tumorigenesis in the intestine. Can J Gastroenterol 2001;15:166-76.
39. Potten CS, Grant HK. The relationship between ionizing radiation-induced apoptosis and stem cells in the small and large intestine. Br J Cancer 1998;78:993-1003.
40. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358: 15-6.
41. Piard F, Martin L, Chapusot C, Ponnelle T, Faivre J. [Genetic pathways in colorectal cancer: interest for the pathologist]. Ann Pathol 2002;22:277-88.
42. Augenlicht LH, Velcich A, Klampfer L, Huang J, Corner G, Aranes M, Laboisse C, Rigas B, Lipkin M, Yang K, Shi Q, Lesser M, et al. Application of gene expression profiling to colon cell maturation, transformation and chemoprevention. J Nutr 2003;133:24105-165.
43. Hursting SD, Slaga TJ, Fischer SM, DiGiovanni J, Phang JM. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. J Natl Cancer Inst 1999;91:215-25.
44. Hursting SD, Perkins SN, Phang JM, Barrett JC. Diet and cancer prevention studies in p53-deficient mice. J Nutr 2001;131:3092S-4S.
45. Hursting SD, Perkins SN, Donehower LA, Davis BJ. Cancer prevention studies in p53-deficient mice. Toxicol Pathol 2001;29:137-41.
46. Reddy BS. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 2004;44:26-35.
47. Corpet DE, Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
48. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors 2002;21:155-64.
49. Grady WM. Genomic instability and colon cancer 2004;23:11-27.
50. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811-6.
51. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, Holt PR. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999;117:838-47.
52. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, Ahnen DJ. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997;57:2452-9.
53. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002;3:166-74.
54. Ravi R, Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res 2002;62:1583-7.
55. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002;62:6323-8.
56. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000;290: 989-92.
57. De Angelis PM, Stokke T, Thorstensen L, Lothe RA, Clausen OP. Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype. Mol Pathol 1998;51:254-61.
58. Zhou XM, Wong BC, Fan XM, Zhang HB, Lin MC, Kung HF, Fan DM, Lam SK. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 2001;22:1393-7.
59. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 2004;13:920-7.
60. Kishimoto Y, Yashima K, Morisawa T, Ohishi T, Marumoto A, Sano A, Idobe Fujii Y, Miura N, Shiota G, Murawaki Y, Hasegawa J. Effects of long-term administration of sulindac on APC mRNA and apoptosis in colons of rats treated with azoxymethane. J Cancer Res Clin Oncol 2002;128:589-95.